TY - JOUR ID - 46853 TI - In Silico Design and Evaluation of PRAME+FliCΔD2D3 as a New Breast Cancer Vaccine Candidate JO - Iranian Journal of Medical Sciences JA - IJMS LA - en SN - 0253-0716 AU - Taheri-Anganeh, Mortaza AU - Savardashtaki, Amir AU - Vafadar, Asma AU - Movahedpour, Ahmad AU - Shabaninejad, Zahra AU - Maleksabet, Amir AU - Amiri, Ahmad AU - Ghasemi, Younes AU - Irajie, Cambyz AD - Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran AD - Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran AD - Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran AD - Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Y1 - 2021 PY - 2021 VL - 46 IS - 1 SP - 52 EP - 60 KW - PRAME antigen KW - Vaccines KW - Breast neoplasms KW - Computer simulation DO - 10.30476/ijms.2019.82301.1029 N2 - Background: The most prevalent cancer in women over the world is breast cancer. Immunotherapy is a promising method to effectively treat cancer patients. Among various immunotherapy methods, tumor antigens stimulate the immune system to eradicate cancer cells. Preferentially expressed antigen in melanoma (PRAME) is mainly overexpressed in breast cancer cells, and has no expression in normal tissues. FliCΔD2D3, as truncated flagellin (FliC), is an effective toll-like receptor 5 (TLR5) agonist with lower inflammatory responses. The objective of the present study was to utilize bioinformatics methods to design a chimeric protein against breast cancer.Methods: The physicochemical properties, solubility, and secondary structures of PRAME+FliCΔD2D3 were predicted using the tools ProtParam, Protein-sol, and GOR IV, respectively. The 3D structure of the chimeric protein was built using I-TASSER and refined with GalaxyRefine, RAMPAGE, and PROCHECK. ANTIGENpro and VaxiJen were used to evaluate protein antigenicity, and allergenicity was checked using AlgPred and Allergen FP. Major histocompatibility complex )MHC( and cytotoxic T-lymphocytes )CTL( binding peptides were predicted using HLApred and CTLpred. Finally, B-cell continuous and discontinuous epitopes were predicted using ABCpred and ElliPro, respectively.Results: The stability and solubility of PRAME+FliCΔD2D3 were analyzed, and its secondary and tertiary structures were predicted. The results showed that the derived peptides could bind to MHCs and CTLs. The designed chimeric protein possessed both linear and conformational epitopes with a high binding affinity to B-cell epitopes. Conclusion: PRAME+FliCΔD2D3 is a stable and soluble chimeric protein that can stimulate humoral and cellular immunity. The obtained results can be utilized for the development of an experimental vaccine against breast cancer. UR - https://ijms.sums.ac.ir/article_46853.html L1 - https://ijms.sums.ac.ir/article_46853_cb1953e06f46127fbc3c7bbc51d3876a.pdf ER -